Pay in 4 interest-free payments of $5.39 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
Additional risk factors commonly present in patients prescribed GLP-1 receptor agonists include: Reduced physical activity and prolonged immobility Hypertension and other cardiovascular comorbidities Dyslipidaemia contributing to atherosclerosis Advanced age , as thrombotic risk increases with ageing Other important VTE risk factors include: Previous VTE or family history of clotting disorders Thrombophilia (inherited or acquired clotting disorders) Active cancer or cancer treatment Oestrogen-containing medications (HRT, combined oral contraceptives) Pregnancy and postpartum period Recent surgery, trauma or hospitalisation Long-haul travel with prolonged immobility Smoking When patients taking GLP-1 receptor agonists experience thrombotic events, it is important to consider these pre-existing risk factors as they often contribute significantly to clotting risk in this population
Get physician-supervised results starting at $75/week
Heres why experience matters when choosing a weight loss clinic: Proven Track Record : With over a decade of successful patient outcomes, we have honed our approach to ensure our patients see real results
FOURIER Trial: Cardiovascular Outcomes With Evolocumab The FOURIER trial (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established atherosclerotic cardiovascular disease (ASCVD) already receiving statin therapy [4]
Clean Injection Site: Wipe the area with an alcohol swab to reduce infection risk
